optional long exon Xa, is located in chromosome 7 (55) . This novel arrangement is almost unprecedented in the mammalian genome, and is species specific. In mice, although the Acat1 gene is also located in chromosome 1, it does not contain the optional exon Xa present in hAcat1. The gene Acat1 is not under the control by the transcription factors sterol regulatory element binding proteins (SREBPs), which control the expression of many genes involved in cellular lipid metabolism (33). In response to cellular cholesterol depletion/repletion, the alteration of ACAT1 activity occurs within 1 to 2 hrs (15), i.e., at a time frame much faster than what is needed for transcriptional control mechanism(s) to be in full operation.
There are at least three human Acat1 mRNAs. The 2.8-and 3.6-knt Acat1 mRNAs contain a short 5' untranslated region (UTR), and comprise most (70-80%) of the total Acat1 mRNAs that are produced from the hAcat1 P1 promoter. These mRNAs are translated as a single 50-kDa protein band in SDS-PAGE, and the resultant protein is the major ACAT1 isoenzyme observed in various human cells and tissues (14) . The 4.3-knt Acat1 mRNA instead contains the alternate long 5'-UTR. This mRNA is produced from two different chromosomes by a novel RNA recombination event. The 5'-UTR contains an alternative initiation codon and an extended in-frame sequence, enabling the chimeric mRNA to produce a larger ACAT1 isoform. In SDS-PAGE, it is detectable as a 56 kDa protein. In human macrophages, the 56 kDa protein is present as a minor ACAT protein (96). The physiological function of the 56 kDa ACAT1 is currently unknown.
In macrophage-like cells, the expression of hAcat1 is up-regulated by interferongamma, a cytokine that exerts many proatherosclerotic effects in model animals (95) , (25) . Urotensin II, the potent vasoconstrictor peptide that can lead to hypertention and atherosclerosis in humans, up-regulates hAcat1 expression in human macrophages (89) .
In addition, the synthetic glucocorticoid dexamethasone, known to promote atherosclerosis in humans (47), up-regulates hAcat1 expression in macrophages.
Consistent with this observation, a glucocorticoid response element is present within the hAcat1 P1 promoter (97). In contrast, hAcat1 expression is down-regulated by adiponectin, an adipocytokine that exerts many anti-atherosclerotic effects in cell culture studies (32). Together, these results support the concept that up-regulation of Acat1 expression in monocytes and macrophages is closely associated with the initiation and progression of the atherosclerosis in tissue culture and in experimental animal models, and perhaps in humans.
B. Biochemical and cellular properties of ACAT1.
Native ACAT1 is an integral membrane protein present in minute quantities in the endoplasmic reticulum (ER). The recombinant 50-kDa human ACAT1 over-expressed in Chinese hamster ovary (CHO) cells has been purified to homogeneity, with retention of catalytic activity (17) . The enzyme responds to cholesterol as its substrate in a sigmoidal manner (17) . Additional kinetic evidences have suggested the presence of a sterol substrate site and a sterol activator site in ACAT1. Cholesterol is superior to oxysterols and to any other sterol as an activator for ACAT1. Upon activation by cholesterol, ACAT1 activity is much increased, and the enzyme is promiscuous towards a variety of sterols with a 3-β-OH configuration in the B Ring as its substrates (102), (60). These results demonstrate that ACAT1 is allosterically activated by cholesterol.
ACAT1 exists as a homotetrameric enzyme in intact cells and in vitro (99).
Deleting the dimer-forming motif near the N-terminus converts the enzyme to a fully functionally active dimeric form (101) . Additional motif(s) involved in forming the other dimer are located near the C-terminus of the enzyme (35). ACAT1 contains one disulfide linkage, and seven free cysteines (Cys). Guo and colleagues employed the membraneimpermeable, sulfhydryl-specific reagent polyethylene glycol 5000 -maleimide (PEG 5000 -mal) to map the disulfide linkage, and to probe the environment of the free sulfhydryls of the enzyme. Their results showed that the first free Cys is located near the N-terminal, in the cytoplasmic side of the ER membrane. The other six free Cys are buried within several transmembrane domains (TMD) of the protein (36). None of the free Cys is required for the ACAT1 enzyme activity (62) ; the disulfide linkage is important for structural stability of the enzyme (36). Regarding the ACAT1 topography, initially, Lin and colleagues used the method of epitope tagging and indirect immunofluorescence in fixed intact cells. Their results suggested that ACAT1 might contain at least 7 TMDs; the region at the C-terminal half is very hydrophobic and might contain additional membrane imbedded segment(s) (58) . More recently, Guo and colleagues (37) used PEG 5000 -mal together with Cys-scanning mutagenesis to further investigate the ACAT1 membrane topography at the C-terminal half, and proposed a revised, 9-TMD model; the active site His460 is located in a hydrophobic environment, within a newly disclosed TMD (TMD#7), between R443-Y462 (Fig. 2) . In contrast to the 9-TMD model, (23) show that, in addition to H460, S456 and D400 are also essential for ACAT1 enzyme activity. These authors suggested that ACAT1 may contain thioesterase activity, and this activity may involve the classical Ser/Asp/His catalytic triad, similar to the serine-dependent hydrolases. The results described above were all based on site-specific mutagenesis studies. For a given enzyme, a protein structural model is needed in order to carry out functional analysis at the refined biochemical level. However, at present, the crystal structure of ACAT1 or any related family member is not available.
C. Regulation and properties of ACAT2.
The second mammalian ACAT gene, designated as Acat2, was identified through its homology to Acat1 ( (3), (67), (10) Each tagged ACAT2 was expressed in the endoplasmic reticulum and was shown to be at least partially enzymatically active. They then used double cytoimmunofluorescence and protease protection assays to monitor the sidedness of the tags along the ER membranes (59) . Their results suggest that ACAT2 may contain only two detectable TMDs, but may contain several additional membrane domains that are only partially embedded in the lipid bilayer. The conserved H434, equivalent to H460 in hACAT1, may be buried in the cytoplasmic side of the ER membrane (Fig.3) . In contrast to the 2-TMD-model, Joyce and colleagues reported that ACAT2 contained five TMDs (46). They prepared a series of the recombinant ACAT2 proteins successively truncated from the C termini after each of the predicted TMDs; the topography was determined by monitoring the membrane sidedness of tags at the C termini of each truncated fusion protein. Both the insertion approach used by Lin and colleagues and the truncation approach used by Joyce and colleagues run the risk of altering the membrane topography of ACAT2. Lin and colleagues did report that each tagged ACAT2 employed was at least partially active enzymatically, while Joyce and colleagues did not report the percentage of ACAT activity remaining in any of the truncated proteins employed. In the future, to resolve the discrepancy, other methods for membrane topography determination that produce minimal structural perturbations of ACAT2 will be needed. However, a major discrepancy, which cannot be explained by differential structural perturbation(s) of ACAT2, exists between the result of Lin and colleagues and the result of Joyce and colleagues: Lin and colleagues showed that the C terminal is in the cytoplasmic side of the ER, whereas Joyce and colleagues showed that the C terminal is in the luminal side of the ER. To determine the location of the C-terminal, both groups used the full length In adult humans, studies carried out by Lee and colleagues (51) and by Chang and colleagues (13) using a combination of immunological staining, immunodepletion, and immunoblot analyses showed that ACAT1 is expressed in many different tissues and cell types, including hepatocytes and Kupffer cells of the liver, adrenal glands, neurons, and macrophages, and accounts for more than 80% of the total ACAT enzyme activity measured in vitro (51), (18, 80) . In a separate study, Parini and colleagues (69) performed similar immunoblot analyses and demonstrated the presence of both ACAT1 and ACAT2 in adult human hepatocytes. These investigators then examined the ACAT enzyme activities in vitro in liver biopsy samples, and showed that, among individual samples, the ACAT2 activities were highly variable whereas the ACAT1 activities were relatively constant. Under the enzyme assay condition employed by these investigators, in 3 of the 4 liver biopsy samples examined, ACAT2 provided more than 50% of the total cholesterol-esterifying activity (69) . It should be noted that the biopsy samples employed by these investigators were all collected from patients affected with gallstone disease; none was from a healthy subject. In another study, Smith and colleagues (83) performed real-time PCR analyses of Acat1 and Acat2 and showed that the ACAT1 mRNAs were on average 9-fold (range, 1.7-to 167-fold) more abundant than the ACAT2 mRNAs.
Among the 17 individual liver samples examined, the ACAT1 mRNA levels were relatively constant, whereas the ACAT2 mRNA levels were much more heterogeneous.
From these studies, it is clear that both ACAT1 and ACAT2 are present in human hepatocytes, though the quantitative aspects of results were different. Together, these studies suggest that the expression of ACAT2 might be inducible under various conditions, whereas the expression of ACAT1 tended to be constitutive. This possibility is supported by the findings that in activated human macrophages and in advanced atherosclerotic plaques, low but significant amounts of ACAT2 mRNA and protein are detectable (79) . In addition, the liver samples of certain patients affected with hepatocellular carcinoma contain highly elevated ACAT2 mRNAs (84). It is also possible that subpopulations of humans may express hepatic ACAT2 at elevated levels constitutively.
Further investigations are needed to test this possibility. In intestines, ACAT2 is shown to be the major isoenzyme, and is mainly expressed in the apices of the intestinal villi (13, 51); its mRNA in duodenum is approximately 3 fold more abundant than that of ACAT1 (83) .
In mice and in monkeys, the ACAT1/ACAT2 distribution in various tissues is similar to that in humans, except for at least one important difference: ACAT2 is highly expressed in the livers of mice and monkeys under normal conditions (64) (53), (69) .
Available data show that in rabbits and mice, the total ACAT enzyme activities in vitro (ACAT1 and ACAT2) are much higher than those in the human livers (discussed in (18) ). In African green monkeys, the hepatic ACAT2 activities are at least 4 fold higher than those found in humans, whereas the hepatic ACAT1 activities in these two species are very similar (69) . Regarding the roles of ACAT1 and ACAT2 in hepatic lipoprotein synthesis and secretion: in various model systems examined, both ACAT1 and ACAT2 are capable of synthesizing cholesteryl esters that contribute to the lipid core in VLDL (85), (45), (56) . In mouse hepatocytes, ACAT2 is the major isoform, and plays a key role in the hepatic storage and packaging of cholesteryl esters into apoB-containing lipoproteins (8) , (90), (52), (6) . In human hepatocytes, both ACAT1 and ACAT2 are present. Whether ACAT1 and/or ACAT2 participate in the biosynthesis of CEs in VLDL in intact human livers is yet to be determined. In mouse intestines, ACAT2 plays a key role in providing cholesteryl esters to chylomicrons (8), (72). Whether the same situation holds true in humans has not been determined.
E. The Acat1 KO and the Acat2 KO mice.
Farese and colleagues (28) created and characterized both the Acat1-/-and Acat2-/-mice. These mice have served as valuable research tools in lipoprotein and atherosclerosis research (reviewed in (9)).
F. ACAT and cellular cholesterol trafficking.
Cells acquire cholesterol mainly via two sources: from the low-density lipoprotein (LDL), and from de novo biosynthesis. Cholesterol molecules from both sources move within the cells, eventually reaching the ER; certain portion of them are converted to cholesteryl esters (CE). In most of the cell types examined, ACAT1 plays the major role in catalyzing the reesterification process. The process of cellular cholesterol trafficking has been reviewed in 2006 (19) , with more recent studies cited in (87) .
ACATS AS DRUG TARGETS A. General properties of the ACAT inhibitors.
During the last several decades, numerous ACAT inhibitors have been synthesized and tested in test tubes, intact cells, animal models, and in humans. The readers are referred to two earlier reviews that summarize the structural characteristics and properties of the ACAT inhibitors (48), (82) . A few of them are structural analogs of the long chain fatty acyl-coenzyme A. Almost all of the ACAT inhibitors are very hydrophobic compounds (40). The hydrophobic nature of these compounds may allow them to enter the membrane lipid bilayer, such that they can interact with residues that play essential role(s) in substrate binding and/or in enzyme catalysis. Interestingly, several natural substances present in the ordinary foodstuffs, such as esculeogenin A in tomatoes (31), and piperine in peppers (63) , exhibit significant ACAT inhibitory activities. In addition, a peptide segment within the apo-serum amyloid A (apoSAA) isoform 2.1 inhibits ACAT activity in macrophages (26).
B. The isotype specific ACAT inhibitors.
Most of the ACAT inhibitors developed in the 1990s inhibit both ACAT1 and ACAT2 without much selectivity. After the ACAT genes were identified, investigators began to develop ACAT isotype selective inhibitors (22), (50), (68) . One of the most notable examples is pyripyropene A (PPPA) which prefers to inhibit ACAT2 over ACAT1 by more than 1000 fold (68) on ACAT1 is yet to be determined.
C. The pros and cons of the ACAT inhibitors to combat atherosclerosis.
Whether ACAT inhibitors will serve as effective anti-atherosclerosis drugs is currently under debate (see (54) , (66), (76), (77) clinical observations suggest that the lipid-rich plaques are more prone to plaque rupture than the lipid poor plaques (27), (57) . Lipid-rich plaques consist of macrophages and smooth muscle cells (75) . In foamy macrophages, ACAT1 is the major isoenzyme (65) .
Cell culture studies suggest that foam cell formation in smooth muscle cells also depends on ACAT1 (65, 74) . In model animals, administration of the isotype-nonselective ACAT inhibitor CI 1011 (5) Other results that disfavor the use of ACAT inhibitor as drug therapy for atherosclerosis include the findings that, when rodent macrophage cell lines were grown under conditions with minimal cellular cholesterol efflux, addition of ACAT inhibitor to the cells caused undesirable build up of cellular free (unesterified) cholesterol, rendering the cells apoptotic (30, 88) . These studies suggest that ACAT inhibitors can be highly toxic to macrophage cells present in the advanced atherosclerotic lesions. It should be pointed out that the cholesterol dependent apoptosis observed in mouse macrophages can not be observed in human macrophages (73) . In addition, in contrast to the results in rodent macrophages, Rong and colleagues showed that ACAT1 inhibition in rat and human aortic smooth muscle cells is nontoxic, and retards foam cell formation (74) . The discrepancy in results described above might be due to difference in the cell systems employed.
Regarding the effects of inhibiting ACAT in the liver: in animals (rodents, rabbits, and monkeys), ACAT2 is the major isoform. In various animal models tested, the ACAT isotype non-selective inhibitor CI 1011 (alone, without statin) significantly reduced serum cholesterol levels (reviewed in (61)). In addition, deletion of ACAT2 gene in mice results in resistance to diet induced hypercholesterolemia and to gallstone formation (8) (72), it also results in protection against atherosclerosis (52, 90) . Another study showed that in a hyperlipidemic mouse model (apoB100-only, LDLr -/-), the in vivo administration of liver-specific antisense oligos against the ACAT2 mRNA reduced ACAT2 protein content only in the liver but not in the intestines; it also successfully reduced serum cholesterol level (4) . The latter result suggests that blocking ACAT2 activity in the liver can significantly lower serum cholesterol levels and reduce atherosclerosis in a manner independent of dietary cholesterol absorption. On the other hand, when tested in human trials, administration of the ACAT inhibitor CI 1011 reduced VLDL cholesterol and triglyceride levels, but failed to significantly reduce the LDLcholesterol levels (44), (61) . These results suggest that the effects of CI 1011 on serum cholesterol levels are species dependent. To provide a possible explanation for these observations: as discussed earlier, the overall ACAT enzyme activity in human livers is much lower than those in rodents, rabbits, and monkeys ( (20), (69)). Thus, hepatic ACAT in humans may not contribute to the CE content present in LDL as much as it does in experimental animal models. The expression of hepatic ACAT2 in humans seems to be highly heterogeneous; inhibiting ACAT2 may effectively reduce the CE content in LDL in subpopulations with elevated hepatic ACAT2. This possibility could be tested in the future.
D. ACAT inhibitors and Alzheimer's disease.
Alzheimer's disease (AD) is the most prevalent neurodegenerative disease in developed countries. It is characterized by massive extracellular accumulation of amyloid plaques, mainly composed of amyloid beta (A-beta) peptide aggregates, and intracellular accumulation of hyperphosphorylated tau protein in the cerebellar area. These events lead to widespread neurodegeneration in the brain. Age and genetic variation in apolipoprotein (apo) E, a plasma cholesterol transport protein, are two of the most important risk factors for AD (71) , (98) . In addition, studies suggest that cholesterol in membranes impacts on production of A-beta (reviewed in (91)). Amyloid precursor protein (APP) can be cleaved via two competing pathways, the alpha and the beta secretase pathways, which are distinguished by the subcellular site of proteolysis and the site of cleavage within APP. Under normal conditions, several proteases are capable of catalyzing the alpha-cleavage after which the gamma-secretase complex, which includes presenilin as a catalytic subunit, further cleaves the APP fragment to produce small, nonamyloidogenic fragments. Similarly, but competing with the alpha-cleavage pathway, the beta-secretase pathway involves sequential cleavages by the beta-secretase and gamma-secretase complexes, which generates A-beta. A-beta is secreted from the cell to the extracellular space, where it aggregates over time. In the central nervous system 2006CB910600 to BLL). We thank Stephanie Murphy for editing the manuscript. Fig.2 . The membrane topography of ACAT1; redrawn with modification from (37). The residues in blue are conserved between ACAT1 and ACAT2; residues in red are conserved between ACAT and diacylglycerol:acyltransferase 1 (DGAT1). TMD7 (R443-E462) and TMD8 (A463-G483) form part of the subunit interaction surface. The Nterminal domain responsible for dimerization of ACAT1 is within residues 43 to 84 (101) . Native Cys are in grey; the active-site His-460 within TMD7 is in red. Fig.3 . The membrane topography of ACAT2; redrawn with modification from (59) . The topography was determined by employing cytoimmunofluorescence after inserting the protein with the antigenic HA tag at various positions (indicated by the arrows). The hydrophobic segment that contains the active site His434 (in red) maybe located within the cytoplasmic side of the membrane, and is highlighted in yellow. 
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